MA25522A1 - Procede de traitement de copd - Google Patents

Procede de traitement de copd

Info

Publication number
MA25522A1
MA25522A1 MA26314A MA26314A MA25522A1 MA 25522 A1 MA25522 A1 MA 25522A1 MA 26314 A MA26314 A MA 26314A MA 26314 A MA26314 A MA 26314A MA 25522 A1 MA25522 A1 MA 25522A1
Authority
MA
Morocco
Prior art keywords
copd
processing process
processing
copd processing
Prior art date
Application number
MA26314A
Other languages
English (en)
Inventor
B Christensen Siegfried
J Torphy Theodore
S Barnette Mary
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MA25522A1 publication Critical patent/MA25522A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/30—Copper compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA26314A 1999-03-01 2001-09-03 Procede de traitement de copd MA25522A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12231599P 1999-03-01 1999-03-01

Publications (1)

Publication Number Publication Date
MA25522A1 true MA25522A1 (fr) 2002-10-01

Family

ID=22401990

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26314A MA25522A1 (fr) 1999-03-01 2001-09-03 Procede de traitement de copd

Country Status (30)

Country Link
US (1) US6670394B1 (fr)
EP (1) EP1156799A4 (fr)
JP (1) JP2002538114A (fr)
KR (1) KR20010102459A (fr)
CN (1) CN1349403A (fr)
AP (1) AP2001002248A0 (fr)
AR (1) AR042369A1 (fr)
AU (1) AU772583B2 (fr)
BG (1) BG105953A (fr)
BR (1) BR0008603A (fr)
CA (1) CA2366036A1 (fr)
CO (1) CO5160248A1 (fr)
CZ (1) CZ20013149A3 (fr)
DZ (1) DZ3019A1 (fr)
EA (1) EA200100930A1 (fr)
HK (1) HK1043935A1 (fr)
HU (1) HUP0200288A3 (fr)
ID (1) ID29888A (fr)
IL (1) IL144992A0 (fr)
MA (1) MA25522A1 (fr)
NO (1) NO20014222L (fr)
NZ (1) NZ513695A (fr)
OA (1) OA11842A (fr)
PE (1) PE20001505A1 (fr)
PL (1) PL352816A1 (fr)
SK (1) SK12372001A3 (fr)
TR (1) TR200102514T2 (fr)
UY (1) UY26040A1 (fr)
WO (1) WO2000051598A1 (fr)
ZA (1) ZA200107186B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2362101A (en) * 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease
US20040005995A1 (en) * 2001-07-26 2004-01-08 Edelson Jeffrey D Method for reducing exacerbations associated with copd
AR029984A1 (es) * 2000-07-27 2003-07-23 Smithkline Beecham Corp Metodo para reducir las exacerbaciones asociadas copd ambito
WO2002088079A2 (fr) * 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Inhibiteurs doubles de pde 7 et pde 4
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
AR039385A1 (es) 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
EA009985B1 (ru) 2003-03-10 2008-04-28 Никомед Гмбх Новый способ получения рофлумиласта
EP1609471A1 (fr) * 2003-03-31 2005-12-28 Kyowa Hakko Kogyo Co., Ltd. Agent therapeutique et/ou agent prophylactique destine aux maladies pulmonaires
WO2005056009A1 (fr) * 2003-12-12 2005-06-23 Kyowa Hakko Kogyo Co., Ltd. Agent therapeutique pour une maladie pulmonaire
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
ES2421916T3 (es) 2005-03-16 2013-09-06 Nycomed Gmbh Forma farmacéutica de sabor enmascarado que contiene roflumilast
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI944549L (fi) * 1992-04-02 1994-11-30 Smithkline Beecham Corp Allergisten ja tulehdussairauksien hoidossa käyttökelpoiset yhdisteet
WO1993019751A1 (fr) * 1992-04-02 1993-10-14 Smithkline Beecham Corporation Composes utilisables dans le traitement des maladies inflammatoires et dans l'inhibition de la production du facteur de necrose tumorale
PT710109E (pt) 1993-06-18 2005-01-31 Smithkline Beecham Corp Metodo para identificar um inibidor de pde iv
US5728705A (en) * 1993-10-04 1998-03-17 The Trustees Of Columbia University In The City Of New York Method of inducing vasorelaxation to treat pulmonary hypertension
CZ283564B6 (cs) * 1993-11-26 1998-05-13 Pfizer Inc. 3-Aryl-2-isoxazolin-5-hydroxamové kyseliny a farmaceutické prostředky na jejich bázi
UY25338A1 (es) 1998-01-07 2001-08-27 Smithkline Beecham Corp Método para tratar copd

Also Published As

Publication number Publication date
UY26040A1 (es) 2000-09-29
CN1349403A (zh) 2002-05-15
ZA200107186B (en) 2002-08-30
DZ3019A1 (fr) 2005-05-20
KR20010102459A (ko) 2001-11-15
NO20014222L (no) 2001-10-29
JP2002538114A (ja) 2002-11-12
US6670394B1 (en) 2003-12-30
ID29888A (id) 2001-10-18
EP1156799A4 (fr) 2004-11-10
AU3386900A (en) 2000-09-21
BR0008603A (pt) 2001-12-26
WO2000051598A1 (fr) 2000-09-08
PE20001505A1 (es) 2001-02-08
EP1156799A1 (fr) 2001-11-28
PL352816A1 (en) 2003-09-08
HK1043935A1 (zh) 2002-10-04
IL144992A0 (en) 2002-06-30
CZ20013149A3 (cs) 2002-04-17
AR042369A1 (es) 2005-06-22
AU772583B2 (en) 2004-04-29
TR200102514T2 (tr) 2002-04-22
EA200100930A1 (ru) 2002-02-28
NZ513695A (en) 2001-09-28
BG105953A (bg) 2002-05-31
SK12372001A3 (sk) 2001-12-03
NO20014222D0 (no) 2001-08-31
HUP0200288A3 (en) 2003-08-28
OA11842A (en) 2005-08-22
CO5160248A1 (es) 2002-05-30
CA2366036A1 (fr) 2000-09-08
AP2001002248A0 (en) 2001-09-30
HUP0200288A2 (hu) 2002-05-29

Similar Documents

Publication Publication Date Title
EP1358650A4 (fr) Procede de traitement multimodal
EP1100119A4 (fr) Procede de traitement au plasma
EP0973396A4 (fr) Procede de traitement du cancer
DE10084419T1 (de) Automatisierte Prozesslinien
FR2797262B1 (fr) Procede de traitement de materiau architectural
FR2814945B1 (fr) Procede de traitement de la canitie
MA25352A1 (fr) Nouvelle methode de traitement
EP1106061A4 (fr) Procede de modification des chromosomes
EP1393708A4 (fr) Procede de traitement des cheveux
AR024800A1 (es) Proceso de produccion de fenil-alcanos
EP1332349A4 (fr) Systeme de traitement automatise
MA25351A1 (fr) Nouvelle methode de traitement
EP1439491A4 (fr) Procede et processeur de traitement de signal
FR2802691B1 (fr) Procede de surveillance maritime
DE60009288D1 (de) Verfahren zum immobilisieren von arsen enthaltenden abfall
ID25641A (id) PROSES PEMURNIAN ε-KAPROLAKTAM MENTAH SECARA KONTINYU
EP1152646A4 (fr) Procede et appareil de traitement au plasma
EP1028457A4 (fr) Procede de traitement au plasma
FR2788234B1 (fr) Procede de chanfreinage
FR2770534B1 (fr) Procede pour enlever des graffitis
EP1162454A4 (fr) Procede de separation bidimensionnelle
FR2790979B1 (fr) Procede et installation pour le traitement des vases
MA25921A1 (fr) Procede de decontamination du gypse
FR2822092B1 (fr) Procede de traitement de noyaux de ceramique
EP1156799A4 (fr) Traitement de la bpco